Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Essex Property Trust, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26 (market cap $4.49B), while Essex Property Trust, Inc. trades at $292.4 (market cap $19.17B). The key difference: Essex Property Trust, Inc. is far larger — about 4.3× ACADIA Pharmaceuticals Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.47% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ESS | |
|---|---|---|
Market Cap | $4.49B | $19.17B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $298.33 |
52-Week Low | $20.06 | $239.61 |
Enterprise Value | $3.69B | $25.89B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Essex Property Trust (ESS) trades at $298.32, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust earnings, beating estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.47. Revenue reached $1.89B in 2025, supported by high gross and net income margins. Recent developments include a $2.59 dividend declaration and inclusion in the Russell Microcap Index.
Outlook remains positive due to strong West Coast rental demand and AI-driven employment growth, but risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $291.68 price target, suggesting limited upside from current levels. Investment appeal hinges on sustained rental growth and balance sheet management amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
